Aveo RCC compound trends toward detrimental survival effect, again

Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) plans to submit an NDA to FDA for its renal cell carcinoma compound in about six months despite reporting preliminary data showing no overall survival benefit for Fotivda tivozanib as a third-line treatment vs. Nexavar sorafenib

Read the full 401 word article

How to gain access

Continue reading with a
two-week free trial.